Adam Fleisher, MD, MAS, Eli Lilly and Company, Indianapolis, IN, shares his thoughts on the future of Alzheimer’s disease drug development, highlighting key approaches under continued investigation. Therapeutics targeting amyloid continue to be a significant area of growth. Ongoing work is aiming to maximize the efficacy of this approach through targeting forms of amyloid other than plaques, such as soluble oligomers. Tau is also an important target for Alzheimer’s disease therapeutics. Designing small molecules and improved delivery methods are a key focus to overcome the challenges of targeting intracellular tau accumulation. Dr Fleisher also highlights inflammation and synaptic dysfunction as important aspects of Alzheimer’s disease pathology that show promise as therapeutic targets. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.
